Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we have very similar systems. But that’s much simpler testing. That’s immunohistochemistry ...
The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for ...
Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy. The ...
Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 ...
-- PD-L1 is a protein involved in the suppression of the immune system, which can impact the body's ability to fight cancer -- The VENTANA PD-L1 (SP142) Assay(1) to determine PD-L1 expression in ...
(MENAFN- EIN Presswire) EINPresswire/ -- The Global PD-L1 Testing and Therapeutics Market, according to DataM Intelligence, was valued at US$ 52.05 billion in 2023, increased to US$ 57.82 billion in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results